Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1
- 1 November 2002
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 18 (6) , 430-441
- https://doi.org/10.1002/dmrr.328
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: Selection of NN2211 for clinical developmentDrugs of the Future, 2001
- Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.International Journal of Obesity, 1999
- ENTEROGLUCAGONAnnual Review of Physiology, 1997
- Glucagon-like peptide-1 and satietyNature, 1997
- Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat.Journal of Clinical Investigation, 1996
- Ileal release of glucagon-like peptide-1 (GLP-1)Digestive Diseases and Sciences, 1995
- Glucagon-like peptide-1 is a physiological incretin in rat.Journal of Clinical Investigation, 1995
- Glucagon‐like peptide 1: A potent glycogenic hormoneFEBS Letters, 1994
- Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in manDigestive Diseases and Sciences, 1993
- Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomyDigestive Diseases and Sciences, 1991